Atrial fibrillation (AF) is the most common cardiac arrhythmia, causing irregular and often rapid heart rhythms. It accounts for approximately 60 million cases globally, with a rising prevalence due to aging populations and lifestyle factors. Novel therapies are emerging, driven by a growing focus on novel anticoagulants, antiarrhythmic drugs, and gene-based treatments. Recent advancements, including AI-driven drug discovery and personalized medicine, are shaping the market. The atrial fibrillation pipeline analysis by Expert Market Research highlights promising drug candidates in various clinical stages, indicating strong growth potential in the coming years, supported by increasing research investments and regulatory approvals.
Major companies involved in the atrial fibrillation pipeline analysis include Huya Bioscience International, Thryv Therapeutics, Inc., and others.
Leading drugs currently in the pipeline include HBI-3000, THRV-1268, and others.
The atrial fibrillation pipeline is expanding due to the development of next-generation anticoagulants such as factor XI inhibitors, the growing prevalence of atrial fibrillation associated with aging populations, and rising investments in gene and RNA-based therapies.
The Atrial Fibrillation Pipeline Analysis Report by Expert Market Research gives comprehensive insights into atrial fibrillation therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for atrial fibrillation. The atrial fibrillation report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atrial fibrillation pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with atrial fibrillation treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atrial fibrillation.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Atrial fibrillation (AF) is an irregular and often rapid heart rhythm caused by chaotic electrical signals in the atria, leading to ineffective blood pumping. It can result from high blood pressure, heart disease, or aging. Symptoms include palpitations, fatigue, and shortness of breath. If untreated, AF increases the risk of stroke and heart failure.
Atrial fibrillation treatments include anticoagulants to prevent clots, beta-blockers or calcium channel blockers to control heart rate, and antiarrhythmic drugs or procedures like catheter ablation to restore normal rhythm. In November 2024, the U.S. FDA approved AOP Health’s Rapiblyk (landiolol) for atrial fibrillation in critical care settings. Clinical studies confirmed its rapid heart rate control with minimal blood pressure reduction, providing a crucial option for patients requiring immediate intervention.
The global prevalence of atrial fibrillation (AF) is estimated to be around 60 million cases, accounting for over 8 million disability-adjusted life years. Studies reveal that from 1990 to 2019, the number of atrial fibrillation and atrial flutter (AF/AFL) cases more than doubled, rising from 28.27 million to 56.67 million. The highest increase occurred in lower-middle-income countries (146.6%) and upper-middle-income countries (145.2%). In low-income countries, prevalence rose by 120.7%. High-income countries experienced a 67.8% increase but still have the highest prevalence at 1,738 cases per 100,000 population.
This section of the report covers the analysis of atrial fibrillation drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total atrial fibrillation clinical trials. Phase IV holds 45.89%, demonstrating a strong presence of approved drugs that enhance treatment accessibility and market growth. Phase III follows with 29.45%, indicating promising late-stage developments. Phase II accounts for 14.38%, reflecting innovation in mid-stage trials. Phase I contributes 8.22%, while Early Phase I at 2.05% highlights emerging advancements. These progressions drive innovation and expand treatment options in the atrial fibrillation market.
The drug molecule categories covered under the atrial fibrillation pipeline analysis include small molecules, monoclonal antibodies, anticoagulants, RNA-based therapies, gene therapy, and others. The atrial fibrillation report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atrial fibrillation.
Potassium channel blockers are emerging as a promising class in the atrial fibrillation pipeline. For instance, AP30663, a KCa2 channel inhibitor, has shown efficacy in animal models. A trial is evaluating its potential in patients with AF episodes lasting seven days or less, comparing intravenous doses of 3 or 5 mg/kg against a placebo.
The EMR report for the atrial fibrillation pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atrial fibrillation therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in atrial fibrillation clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for atrial fibrillation. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of atrial fibrillation drug candidates.
HBI-3000, an intravenous antiarrhythmic drug sponsored by Huyabio International, LLC, is being evaluated in a Phase II study for the conversion of recent-onset atrial fibrillation (AF). This two-stage study includes dose escalation followed by a placebo-controlled phase to assess safety, efficacy, and tolerability. Containing sulcardine, HBI-3000 aims to reduce life-threatening arrhythmias, addressing limitations of current AF treatments.
THRV-1268, sponsored by Thryv Therapeutics, Inc., is undergoing a Phase I study to assess its safety, tolerability, and pharmacokinetics in healthy adults. This novel SGK1 inhibitor targets pathways associated with arrhythmias, fibrosis, and heart failure. With an estimated enrollment of 74 participants, the study involves single and multiple ascending doses to evaluate QTc interval effects and food interactions.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Atrial Fibrillation Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for atrial fibrillation. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within atrial fibrillation pipeline insights.
Atrial Fibrillation Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share